Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco 2026-10-21T19:22:10-07:00January 3rd, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit. 2026-10-21T19:20:01-07:00August 1st, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML 2026-10-26T12:21:04-07:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
